Written answer
Cancer Services
1801. Deputy Fionntán Ó Súilleabháin asked the Minister for Health the steps she is taking to ensure that all women are informed if they have dense breast tissue following breast screening; if she will provide a timeline for the introduction of breast density reporting within the BreastCheck programme; and if she will ensure equitable access to any additional screening services recommended for women with dense breasts, in order to improve the early detection of breast cancer and reduce inequalities in cancer outcome. [75826/26]
Comment on this
As Minister for Health, I am dedicated to enhancing Ireland’s population screening programmes, which are a vital component of our health services. They enable early treatment and care for many people, thereby enhancing the overall health of our community.
The Programme for Government commits to extend the ages for BreastCheck screening programme in line with updated standards from the Health Information and Quality Authority (HIQA).
BreastCheck, the National Breast Screening Programme, currently invites women aged 50 to 69 years at regular intervals to have a screening mammogram. The Government has made significant investments in cancer screening programmes in recent years. In 2026, 20 (WTE) positions were allocated to National Screening Services, of which 12 were assigned to BreastCheck.
Consideration of any changes to Ireland’s screening programmes will be facilitated through established evidence-driven protocols. The National Screening Advisory Committee (NSAC) is the independent expert group that advises me, as Minister for Health on any proposed changes to Ireland’s screening programmes.
At the request of NSAC, the Health Information and Quality Authority (HIQA) has commenced a Health Technology Assessment (HTA) to consider proposals for the expansion of the BreastCheck programme. This review comprises two elements; the proposed extension of the age range eligibility to those aged 45-49 and 70-74, and also the potential introduction of a standardised breast density notification.
HTAs facilitate the assessment of relevant evidence and knowledge on the effects and consequences of healthcare technologies to guide decisions regarding the appropriate use of technology and efficient allocation of resources. They involve a multi-disciplinary assessment of the clinical, economic, ethical, legal and societal perspectives that may be impacted by the introduction of a new technology. HTAs are time intensive and rigorous processes that must be afforded the necessary amount of time to complete. This is particularly relevant in the context of the BreastCheck HTA, which is considering three distinct areas, the potential to increase the age eligibility, to decrease the age eligibility and the potential notification of breast density.
It is expected that the final HIQA HTA report will be submitted to the National Screening Advisory Committee (NSAC) before the end of 2027. Once received, NSAC will consider the findings and make a recommendation to me for a decision.
It should be emphasised that population-based screening programmes are intended for individuals without symptoms. If someone has any concerns or symptoms related to their breasts, they should not attend screening but instead contact a medical professional for appropriate advice.
It is also important that every woman is breast aware, which means knowing what is normal for them so that if any unusual change occurs, they will recognise it. Further information is available on: www.breastcheck.ie